Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amgen brought the first DLL3-targeting drug to market earlier this year after it got US approval for bispecific T-cell engager (BiTE) Imdelltra (tarlatamab) for adults with advanced, extensive ...

the latter two acquired via Amgen's ~$28bn deal to acquire Horizon Therapeutics in 2023, alongside gout therapy Krystexxa, and in oncology, Blincyto and Imdelltra (see table above for mechanism of ...

Finally, in oncology, Amgen is expecting a Phase 3 study readout in the first half of 2025 on Imdelltra a first-in-class treatment for NSCLC. Blincyto is coming off a successful Phase 3 study ...

Amgen’s product sales are expected to have ... respectively. The U.S. launch of Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024, is ...

Amgen reports that in a study of 99 adult patients who had two or more prior treatments, 40 % responded to Imdelltra, meaning their tumor shrank or disappeared.

Amgen successfully launched two next-generation products ... Lumakras/Lumykras, Tezspire, Imdelltra, Tavneos and Kanjinti, Mvasi and Amgevita biosimilars. AMGN is a Zacks Rank #3 (Hold) stock, with a ...

Amgen successfully launched two next-generation ... Lumakras/Lumykras, Tezspire, Imdelltra, Tavneos and Kanjinti, Mvasi and Amgevita biosimilars. AMGN sits at a Zacks Rank #3 (Hold), holds a ...

Amgen reported fourth-quarter 2024 adjusted ... up 10% from the year-ago period. Imdelltra (tarlatamab), approved for pre-treated advanced small cell lung cancer (ES-SCLC) in May 2024, recorded ...